The HUMN and HUMNxL international collaboration projects on human micronucleus assays in lymphocytes and buccal cells-past, present and future

Michael Fenech, Nina Holland, Errol Zeiger, Wushou P. Chang, Sema Burgaz, Philip Thomas, Claudia Bolognesi, Siegfried Knasmueller, Micheline Kirsch-Volders, Stefano Bonassi

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

The International Human Micronucleus (HUMN) Project (www.humn.org) was founded in 1997 to coordinate worldwide research efforts aimed at using micronucleus (MN) assays to study DNA damage in human populations. The central aims were to (i) collect databases on baseline MN frequencies and associated methodological, demographic, genetic and exposure variables, (ii) determine those variables that affect MN frequency, (iii) establish standardised protocols for performing assays so that data comparisons can be made more reliably across laboratories and countries and (iv) evaluate the association of MN frequency with disease outcomes both cross-sectionally and prospectively. In the first 10 years of the HUMN project, all of these objectives were achieved successfully for the MN assay using the cytokinesis-block micronucleus (CBMN) assay in human peripheral blood lymphocytes and the findings were published in a series of papers that are among the most highly cited in the field. The CBMN protocol and scoring criteria are now standardised; the effect of age, gender and smoking status have been defined, and it was shown prospectively using a database of almost 7000 subjects that an increased MN frequency in lymphocytes predicts cancer risk. More recently in 2007, the HUMN coordinating group decided to launch an equivalent project focussed on the human MN assay in buccal epithelial cells because it provides a complementary method for measuring MN in a tissue that is easily accessible and does not require tissue culture. This new international project is now known as the human MN assay in exfoliated cells (HUMNxL). At present, a database for >5000 subjects worldwide has been established for the HUMNxL project. The inter-laboratory slide-scoring exercise for the HUMNxL project is at an advanced stage of planning and the analyses of data for methodological, demographic, genetic, lifestyle and exposure variables are at a final stage of completion. Future activities will be aimed at (i) defining the genetic variables that affect MN frequencies, (ii) validation of the various automated scoring systems based on image analysis, flow cytometry and laser scanning cytometry, (iii) standardisation of protocols for scoring micronuclei (MNi) in cells from other tissues, e.g. erythrocyte and nasal cells and (iv) prospective association studies with pregnancy complications, developmental defects, childhood cancers, cardiovascular disease and neurodegenerative diseases.

Original languageEnglish
Pages (from-to)239-245
Number of pages7
JournalMutagenesis
Volume26
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Micronucleus Tests
Lymphocytes
Cheek
Assays
Cytokinesis
Databases
Association reactions
Neurodegenerative diseases
Tissue
Laser Scanning Cytometry
Tissue culture
Demography
Flow cytometry
Pregnancy Complications
Image analysis
Standardization
Nose
Neurodegenerative Diseases
Blood
DNA Damage

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

The HUMN and HUMNxL international collaboration projects on human micronucleus assays in lymphocytes and buccal cells-past, present and future. / Fenech, Michael; Holland, Nina; Zeiger, Errol; Chang, Wushou P.; Burgaz, Sema; Thomas, Philip; Bolognesi, Claudia; Knasmueller, Siegfried; Kirsch-Volders, Micheline; Bonassi, Stefano.

In: Mutagenesis, Vol. 26, No. 1, 01.2011, p. 239-245.

Research output: Contribution to journalArticle

Fenech, M, Holland, N, Zeiger, E, Chang, WP, Burgaz, S, Thomas, P, Bolognesi, C, Knasmueller, S, Kirsch-Volders, M & Bonassi, S 2011, 'The HUMN and HUMNxL international collaboration projects on human micronucleus assays in lymphocytes and buccal cells-past, present and future', Mutagenesis, vol. 26, no. 1, pp. 239-245. https://doi.org/10.1093/mutage/geq051
Fenech, Michael ; Holland, Nina ; Zeiger, Errol ; Chang, Wushou P. ; Burgaz, Sema ; Thomas, Philip ; Bolognesi, Claudia ; Knasmueller, Siegfried ; Kirsch-Volders, Micheline ; Bonassi, Stefano. / The HUMN and HUMNxL international collaboration projects on human micronucleus assays in lymphocytes and buccal cells-past, present and future. In: Mutagenesis. 2011 ; Vol. 26, No. 1. pp. 239-245.
@article{829619b578cf4548ab1c8297d41ab6ab,
title = "The HUMN and HUMNxL international collaboration projects on human micronucleus assays in lymphocytes and buccal cells-past, present and future",
abstract = "The International Human Micronucleus (HUMN) Project (www.humn.org) was founded in 1997 to coordinate worldwide research efforts aimed at using micronucleus (MN) assays to study DNA damage in human populations. The central aims were to (i) collect databases on baseline MN frequencies and associated methodological, demographic, genetic and exposure variables, (ii) determine those variables that affect MN frequency, (iii) establish standardised protocols for performing assays so that data comparisons can be made more reliably across laboratories and countries and (iv) evaluate the association of MN frequency with disease outcomes both cross-sectionally and prospectively. In the first 10 years of the HUMN project, all of these objectives were achieved successfully for the MN assay using the cytokinesis-block micronucleus (CBMN) assay in human peripheral blood lymphocytes and the findings were published in a series of papers that are among the most highly cited in the field. The CBMN protocol and scoring criteria are now standardised; the effect of age, gender and smoking status have been defined, and it was shown prospectively using a database of almost 7000 subjects that an increased MN frequency in lymphocytes predicts cancer risk. More recently in 2007, the HUMN coordinating group decided to launch an equivalent project focussed on the human MN assay in buccal epithelial cells because it provides a complementary method for measuring MN in a tissue that is easily accessible and does not require tissue culture. This new international project is now known as the human MN assay in exfoliated cells (HUMNxL). At present, a database for >5000 subjects worldwide has been established for the HUMNxL project. The inter-laboratory slide-scoring exercise for the HUMNxL project is at an advanced stage of planning and the analyses of data for methodological, demographic, genetic, lifestyle and exposure variables are at a final stage of completion. Future activities will be aimed at (i) defining the genetic variables that affect MN frequencies, (ii) validation of the various automated scoring systems based on image analysis, flow cytometry and laser scanning cytometry, (iii) standardisation of protocols for scoring micronuclei (MNi) in cells from other tissues, e.g. erythrocyte and nasal cells and (iv) prospective association studies with pregnancy complications, developmental defects, childhood cancers, cardiovascular disease and neurodegenerative diseases.",
author = "Michael Fenech and Nina Holland and Errol Zeiger and Chang, {Wushou P.} and Sema Burgaz and Philip Thomas and Claudia Bolognesi and Siegfried Knasmueller and Micheline Kirsch-Volders and Stefano Bonassi",
year = "2011",
month = "1",
doi = "10.1093/mutage/geq051",
language = "English",
volume = "26",
pages = "239--245",
journal = "Mutagenesis",
issn = "0267-8357",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - The HUMN and HUMNxL international collaboration projects on human micronucleus assays in lymphocytes and buccal cells-past, present and future

AU - Fenech, Michael

AU - Holland, Nina

AU - Zeiger, Errol

AU - Chang, Wushou P.

AU - Burgaz, Sema

AU - Thomas, Philip

AU - Bolognesi, Claudia

AU - Knasmueller, Siegfried

AU - Kirsch-Volders, Micheline

AU - Bonassi, Stefano

PY - 2011/1

Y1 - 2011/1

N2 - The International Human Micronucleus (HUMN) Project (www.humn.org) was founded in 1997 to coordinate worldwide research efforts aimed at using micronucleus (MN) assays to study DNA damage in human populations. The central aims were to (i) collect databases on baseline MN frequencies and associated methodological, demographic, genetic and exposure variables, (ii) determine those variables that affect MN frequency, (iii) establish standardised protocols for performing assays so that data comparisons can be made more reliably across laboratories and countries and (iv) evaluate the association of MN frequency with disease outcomes both cross-sectionally and prospectively. In the first 10 years of the HUMN project, all of these objectives were achieved successfully for the MN assay using the cytokinesis-block micronucleus (CBMN) assay in human peripheral blood lymphocytes and the findings were published in a series of papers that are among the most highly cited in the field. The CBMN protocol and scoring criteria are now standardised; the effect of age, gender and smoking status have been defined, and it was shown prospectively using a database of almost 7000 subjects that an increased MN frequency in lymphocytes predicts cancer risk. More recently in 2007, the HUMN coordinating group decided to launch an equivalent project focussed on the human MN assay in buccal epithelial cells because it provides a complementary method for measuring MN in a tissue that is easily accessible and does not require tissue culture. This new international project is now known as the human MN assay in exfoliated cells (HUMNxL). At present, a database for >5000 subjects worldwide has been established for the HUMNxL project. The inter-laboratory slide-scoring exercise for the HUMNxL project is at an advanced stage of planning and the analyses of data for methodological, demographic, genetic, lifestyle and exposure variables are at a final stage of completion. Future activities will be aimed at (i) defining the genetic variables that affect MN frequencies, (ii) validation of the various automated scoring systems based on image analysis, flow cytometry and laser scanning cytometry, (iii) standardisation of protocols for scoring micronuclei (MNi) in cells from other tissues, e.g. erythrocyte and nasal cells and (iv) prospective association studies with pregnancy complications, developmental defects, childhood cancers, cardiovascular disease and neurodegenerative diseases.

AB - The International Human Micronucleus (HUMN) Project (www.humn.org) was founded in 1997 to coordinate worldwide research efforts aimed at using micronucleus (MN) assays to study DNA damage in human populations. The central aims were to (i) collect databases on baseline MN frequencies and associated methodological, demographic, genetic and exposure variables, (ii) determine those variables that affect MN frequency, (iii) establish standardised protocols for performing assays so that data comparisons can be made more reliably across laboratories and countries and (iv) evaluate the association of MN frequency with disease outcomes both cross-sectionally and prospectively. In the first 10 years of the HUMN project, all of these objectives were achieved successfully for the MN assay using the cytokinesis-block micronucleus (CBMN) assay in human peripheral blood lymphocytes and the findings were published in a series of papers that are among the most highly cited in the field. The CBMN protocol and scoring criteria are now standardised; the effect of age, gender and smoking status have been defined, and it was shown prospectively using a database of almost 7000 subjects that an increased MN frequency in lymphocytes predicts cancer risk. More recently in 2007, the HUMN coordinating group decided to launch an equivalent project focussed on the human MN assay in buccal epithelial cells because it provides a complementary method for measuring MN in a tissue that is easily accessible and does not require tissue culture. This new international project is now known as the human MN assay in exfoliated cells (HUMNxL). At present, a database for >5000 subjects worldwide has been established for the HUMNxL project. The inter-laboratory slide-scoring exercise for the HUMNxL project is at an advanced stage of planning and the analyses of data for methodological, demographic, genetic, lifestyle and exposure variables are at a final stage of completion. Future activities will be aimed at (i) defining the genetic variables that affect MN frequencies, (ii) validation of the various automated scoring systems based on image analysis, flow cytometry and laser scanning cytometry, (iii) standardisation of protocols for scoring micronuclei (MNi) in cells from other tissues, e.g. erythrocyte and nasal cells and (iv) prospective association studies with pregnancy complications, developmental defects, childhood cancers, cardiovascular disease and neurodegenerative diseases.

UR - http://www.scopus.com/inward/record.url?scp=78650639748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650639748&partnerID=8YFLogxK

U2 - 10.1093/mutage/geq051

DO - 10.1093/mutage/geq051

M3 - Article

C2 - 21164208

AN - SCOPUS:78650639748

VL - 26

SP - 239

EP - 245

JO - Mutagenesis

JF - Mutagenesis

SN - 0267-8357

IS - 1

ER -